Last $0.62 USD
Change Today -0.0436 / -6.53%
Volume 500.3K
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

response genetics inc (RGDX) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/3/14 - $1.56
52 Week Low
12/26/14 - $0.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RESPONSE GENETICS INC (RGDX)

Related News

No related news articles were found.

response genetics inc (RGDX) Related Businessweek News

No Related Businessweek News Found

response genetics inc (RGDX) Details

Response Genetics, Inc., a life science company, is engaged in the research, development, marketing, and sale of pharmacogenomic tests for use in the treatment of cancer primarily in the United States, Asia, and Europe. It develops genetic tests that measure predictive factors for therapy response in tumor tissue samples. The company offers tests for non-small cell lung cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, and breast cancer patients’ tumor tissue specimens through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, and ResponseDX: and Tissue of Origin test suites. It also provides HER2 mutation detection, cKIT mutation detection, MET gene amplification, and UGT1A1 SNP tests, including ROS1 FISH, ROS1 RT-PCR, c-MET, HER2 FISH, and VEGFR2. In addition, the company focuses on the development of various diagnostic tests for predicting therapy response and determining the diagnosis and prognosis of solid tumors in cancer patients. It serves community based oncologists, pathologists, physician offices, and hospitals, as well as pharmaceutical companies and cancer care centers through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

109 Employees
Last Reported Date: 03/31/14
Founded in 1999

response genetics inc (RGDX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $900.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $296.7K
Vice President of Research & Development
Total Annual Compensation: $333.5K
Compensation as of Fiscal Year 2013.

response genetics inc (RGDX) Key Developments

Response Genetics, Inc. Enters into First Amendment to Credit Agreement

On February 3, 2015, Response Genetics Inc. entered into a first amendment to that certain credit agreement, dated July 30, 2014, with SWK Funding LLC, as the agent, and the lenders (including SWK Funding LLC) party thereto from time to time (lenders). Pursuant to the amendment, the company drew an additional $1,500,000 of the maximum $12,000,000 term loan commitment amount increasing the total amount advanced to the company under the credit agreement to $10,000,000. The maturity date for the term loan remains July 30, 2020 or such earlier date on which the loan commitment amount is terminated pursuant to the terms of the credit agreement. The remaining $2,000,000 of the loan commitment amount may be advanced to the company upon written request to the agent during the period beginning on the amendment closing date and ending February 28, 2016 provided that (i) no default or event of default has occurred or is continuing under the credit agreement, (ii) the aggregate revenue recognized by the company and any of its subsidiaries during any period of 4 consecutive fiscal quarters ending prior to December 31, 2015, exceeds a certain dollar amount threshold and (iii) the agent has received an executed warrant to purchase a number of shares of common stock equal to the number obtained when the amount of the subsequent term loan is multiplied by 15% and the product is divided by the exercise price of such warrant.

Response Genetics Receives Delisting Determination Letter From Nasdaq

On December 19, 2014, Response Genetics, Inc. received a delisting determination letter from the staff of The NASDAQ Stock Market LLC (Nasdaq) due to the Company not regaining compliance with The Nasdaq Capital Market minimum bid price of $1.00 requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2) within 180 days or by December 17, 2014. The delisting determination letter also stated that the Company is not eligible for an additional 180-day extension to regain compliance with the minimum bid price rule because the Company does not meet the minimum $2,500,000 in stockholders’ equity standard for continued listing under Nasdaq Listing Rule 5550(b)(1). Pursuant to the determination letter, unless the Company requests an appeal of this determination by 4:00 p.m. (Eastern Time) on December 26, 2014, the Company’s common stock will be delisted from The Nasdaq Capital Market, trading of the Company’s common stock will be suspended at the opening of business on December 30, 2014, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. If the Company requests an appeal, the Company will be asked to provide a Hearing Panel with a plan to regain compliance. The Company’s plan would need to include a discussion of the events that the Company believes will enable it to timely regain compliance and a commitment to effect a reverse stock split, if necessary. If the Company appeals the delisting determination, the appeal will stay the suspension of the Company’s securities and the filing of the Form 25-NSE until the hearing process is completed. The Company intends to timely request a hearing to appeal the staff’s determination. While the appeal process is pending, the suspension of trading of the Company’s common stock will be stayed, and the Company’s common stock will continue to trade on the Nasdaq Capital Market until the hearing process concludes and the Hearing Panel issues a written decision. There can be no assurance that the Hearing Panel will grant the Company’s request for a suspension of delisting or continued listing on Nasdaq. If the Company’s common stock ceases to be listed for trading on the Nasdaq Capital Market, the Company expects that its common stock would be traded on the Over-the-Counter Bulletin Board on or about the same day.

Response Genetics, Inc Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Response Genetics, Inc Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGDX:US $0.62 USD -0.0436

RGDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $3.06 USD +0.01
NeoGenomics Inc $4.54 USD +0.13
Psychemedics Corp $16.41 USD +0.58
Rosetta Genomics Ltd $3.41 USD -0.10
Veracyte Inc $8.79 USD +0.15
View Industry Companies

Industry Analysis


Industry Average

Valuation RGDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book 12.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESPONSE GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at